Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies - PubMed (original) (raw)

. 2007 Oct 12;318(5848):287-90.

doi: 10.1126/science.1142946. Epub 2007 Sep 13.

Alec C Kimmelman, Haoqiang Ying, Roustem Nabioullin, Aditya H Ponugoti, Ruprecht Wiedemeyer, Alexander H Stegh, James E Bradner, Keith L Ligon, Cameron Brennan, Lynda Chin, Ronald A DePinho

Affiliations

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

Jayne M Stommel et al. Science. 2007.

Abstract

Targeted therapies that inhibit receptor tyrosine kinases (RTKs) and the downstream phosphatidylinositol 3-kinase (PI3K) signaling pathway have shown promising anticancer activity, but their efficacy in the brain tumor glioblastoma multiforme (GBM) and other solid tumors has been modest. We hypothesized that multiple RTKs are coactivated in these tumors and that redundant inputs drive and maintain downstream signaling, thereby limiting the efficacy of therapies targeting single RTKs. Tumor cell lines, xenotransplants, and primary tumors indeed show multiple concomitantly activated RTKs. Combinations of RTK inhibitors and/or RNA interference, but not single agents, decreased signaling, cell survival, and anchorage-independent growth even in glioma cells deficient in PTEN, a frequently inactivated inhibitor of PI3K. Thus, effective GBM therapy may require combined regimens targeting multiple RTKs.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources